Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

Thursday, January 31, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

EAST NORRITON, Pa., Jan. 30 Tengion Inc., a clinical stageregenerative medicine company focused on the development of neo-organs andneo-vessels, announced today that Steven Nichtberger, M.D., President andChief Executive Officer, will be presenting at the Merrill Lynch GlobalPharmaceutical, Biotechnology and Medical Device Conference on Tuesday,February 5, 2008 at 9:20 a.m. EST. The conference will be held at the GrandHyatt Hotel in New York City.

About Tengion

Tengion, a clinical stage biotechnology company, has pioneered theAutologous Organ Regeneration Platform(TM) that catalyzes the body's innateability to regenerate. Tengion's neo-organs and neo-tissues in development,such as bladders and vessels, combine biocompatible materials and a patient'sown (autologous) cells to regenerate diseased and failing organs and tissues.Tengion's product candidates have the potential to cure -- rather than treat-- organ and tissue failure, enabling people to lead healthier lives withoutdonor transplants or the side effects of related therapies. For moreinformation on the company and current clinical trials, visit Tengion onlineat: http://www.tengion.com.

SOURCE Tengion Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store